Improving Diabetes - decision tool gains recognition

The Improving Diabetes Steering Committee (IDSC) is a multi-disciplinary group of healthcare professionals (HCPs). It provides practical guidance for appropriate use of the sodium-glucose cotransporter-2 inhibitor (SGLT2i) medicines in people with type 2 diabetes mellitus (T2DM).

The Committee produces materials that review the evidence and guidelines relating to use of SGLT2is , including their risk–benefit profile in reducing the risk of cardiovascular, renal and metabolic (CVRM) complications.

The IDSC has produced a key Decision Tool to help practitioners provide person-centred care.

The tool in included in the supplementary information in this recently published paper: SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review | Diabetes Therapy (springer.com)

Full Tool:  https://static-content.springer.com/esm/art%3A10.1007%2Fs13300-024-01550-5/MediaObjects/13300_2024_1550_MOESM1_ESM.pdf

Wall chart: https://static-content.springer.com/esm/art%3A10.1007%2Fs13300-024-01550-5/MediaObjects/13300_2024_1550_MOESM2_ESM.pdf

I’m so pleased with the outputs from the IDSC and hugely proud to have been part of this project.  I strongly feel that the most recent paper and Decision Tool is the BEST ever and will bring so much to so many! 

A big thank you to our medical writer, the authors and Menarini for their support.